Latest Pharma Insights
GlycoNex To Sweeten Novel Glycan Target For ADC In Phase I
Taiwanese biotech has high hopes of successfully mounting first glycan antibody onto an antibody-drug conjugate.
Scrip - May 15, 2026
Taiwanese biotech has high hopes of successfully mounting first glycan antibody onto an antibody-drug conjugate.
Scrip - May 15, 2026
US Consumer Health Weekly News Digest: Business, Regulation, Science
FDA notes OMUFA due date changes, nonpayment penalties; plans "dietary substance for use to supplement the diet" guidance; Makary makes consumer health mark; AHPA reports "Year of Transition & Impact"; Herbalife sales up nearly 8%; and North Carolina CBD firm's sales up nearly 20%.
HBW Insight - May 15, 2026
FDA notes OMUFA due date changes, nonpayment penalties; plans "dietary substance for use to supplement the diet" guidance; Makary makes consumer health mark; AHPA reports "Year of Transition & Impact"; Herbalife sales up nearly 8%; and North Carolina CBD firm's sales up nearly 20%.
HBW Insight - May 15, 2026
GlycoNex To Sweeten Novel Glycan Target For ADC In Phase I
Taiwanese biotech has high hopes of successfully mounting first glycan antibody onto an antibody-drug conjugate.
Scrip - May 15, 2026
Taiwanese biotech has high hopes of successfully mounting first glycan antibody onto an antibody-drug conjugate.
Scrip - May 15, 2026
Making Robotic Surgery Affordable Is Florida Company’s ‘Mantra’
SS Innovations is confident that the track record of its Mantra robotic system will result in an FDA clearance sometime this year. The company is also seeking the CE mark for Mantra, which has already been cleared for use in 11 countries. The company’s CEO discusses the robotic system.
Medtech Insight - May 14, 2026
SS Innovations is confident that the track record of its Mantra robotic system will result in an FDA clearance sometime this year. The company is also seeking the CE mark for Mantra, which has already been cleared for use in 11 countries. The company’s CEO discusses the robotic system.
Medtech Insight - May 14, 2026
EU Details AI Act Medtech Compromise
New AI Act text mandates the European Commission to reduce regulatory burden, but bottlenecks are still expected.
Medtech Insight - May 14, 2026
New AI Act text mandates the European Commission to reduce regulatory burden, but bottlenecks are still expected.
Medtech Insight - May 14, 2026
FDA Issues Final Guidance For Patient-Matched Orthopedic Surgical Guides
The final guidance sets out testing, documentation and design process expectations for devices shaped from patient imaging to position orthopedic implants but leaves key thresholds for industry to interpret.
Medtech Insight - May 14, 2026
The final guidance sets out testing, documentation and design process expectations for devices shaped from patient imaging to position orthopedic implants but leaves key thresholds for industry to interpret.
Medtech Insight - May 14, 2026
AstraZeneca Joins Pharma’s Agentic AI Race With Three-Year Owkin Deal
Owkin will build custom agents on its K Pro platform to track rival trials, forecast outcomes and scan patents for AstraZeneca — extending a partnership that already produced a BRCA prescreening tool.
Medtech Insight - May 14, 2026
Owkin will build custom agents on its K Pro platform to track rival trials, forecast outcomes and scan patents for AstraZeneca — extending a partnership that already produced a BRCA prescreening tool.
Medtech Insight - May 14, 2026
US Consumer Health Weekly News Digest: Business, Regulation, Science
FDA notes OMUFA due date changes, nonpayment penalties; plans "dietary substance for use to supplement the diet" guidance; Makary makes consumer health mark; AHPA reports "Year of Transition & Impact"; Herbalife sales up nearly 8%; and North Carolina CBD firm's sales up nearly 20%.
HBW Insight - May 15, 2026
FDA notes OMUFA due date changes, nonpayment penalties; plans "dietary substance for use to supplement the diet" guidance; Makary makes consumer health mark; AHPA reports "Year of Transition & Impact"; Herbalife sales up nearly 8%; and North Carolina CBD firm's sales up nearly 20%.
HBW Insight - May 15, 2026
Mylan Epoprostenol Win Clarifies US Measurement Rules And Equivalents Limits
Viatris’ Mylan has prevailed at the Federal Circuit after the court held Actelion’s Veletri formulation claims required pH measurement at standard temperature, while the claims could not be saved through the doctrine of equivalents.
Generics Bulletin - May 14, 2026
Viatris’ Mylan has prevailed at the Federal Circuit after the court held Actelion’s Veletri formulation claims required pH measurement at standard temperature, while the claims could not be saved through the doctrine of equivalents.
Generics Bulletin - May 14, 2026
The Generics Bulletin Podcast: Biosimilars Conference Report And Big M&A Deals
Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, as well as talking about the latest big deals in biosimilars and what is behind them.
Generics Bulletin - May 14, 2026
Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, as well as talking about the latest big deals in biosimilars and what is behind them.
Generics Bulletin - May 14, 2026
Medtech’s Hottest Turf War: Why Every Medtech Giant Wants A Piece Of The IVL Market
Intravascular lithotripsy spent years as Shockwave's niche. With J&J's acquisition complete and rivals closing in, the market for cracking arterial calcium is about to get competitive.
In Vivo - May 14, 2026
Intravascular lithotripsy spent years as Shockwave's niche. With J&J's acquisition complete and rivals closing in, the market for cracking arterial calcium is about to get competitive.
In Vivo - May 14, 2026
Dealmaking Quarterly Statistics, Q1 2026
During Q1, biopharma merger and acquisition deal value reached $54bn and drew in $88.7bn in potential deal value from alliances. Device company M&A values reached $27bn, while in vitro diagnostics and research tools players’ M&A activity totaled $986m.
In Vivo - May 14, 2026
During Q1, biopharma merger and acquisition deal value reached $54bn and drew in $88.7bn in potential deal value from alliances. Device company M&A values reached $27bn, while in vitro diagnostics and research tools players’ M&A activity totaled $986m.
In Vivo - May 14, 2026